MORGAN STANLEY PLC/CALL/MODERNA/105/0.1/20.12.24 | Real-time Bid/Ask 10:07:58 2024-07-04 am EDT | ||
| 2.41 EUR / 2.48 EUR | +2.30% |
|
| Current month | -6.64% | ||
| 1 month | -50.21% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-04 | 2.43 | +1.67% |
| 24-07-03 | 2.39 | -3.63% |
| 24-07-02 | 2.48 | +2.48% |
| 24-07-01 | 2.42 | -5.47% |
| 24-06-28 | 2.56 | -7.25% |
Delayed Quote Börse Stuttgart
Last update July 04, 2024 at 10:05 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | Morgan Stanley |
| WKN | MB9KNX |
| ISIN | DE000MB9KNX7 |
| Date issued | 2023-08-08 |
| Strike | 105 $ |
| Maturity | 2024-12-20 (169 Days) |
| Parity | 10 : 1 |
| Emission price | 3.15 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.6 € |
|---|---|
| Lowest since issue | 0.63 € |
| Spread | 0.07 € |
| Spread % | 2.79% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
116
USD
Average target price
145.9
USD
Spread / Average Target
+25.79%
- Stock Market
- Warrants
- Warrant
